Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Alessia Maiorino
Cost Per Responder for Ixekizumab and Other Biologic Drugs Approved for the Treatment of Moderate-To-Severe Plaque Psoriasis in Italy
Global and Regional Health Technology Assessment
Health Policy
Related publications
Pss33 - Secukinumab as First Biologic Treatment: A Cost Per Responder Analysis Compared With Licensed Biologics, for Moderate to Severe Psoriasis in Argentina
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pss16 - Cost Per Responder Analysis of Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam Versus Non-Biologic Systemic Therapy in the Treatment of Moderate to Severe Plaque Psoriasis
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pss17 - Cost Per Responder Analysis of Brodalumab Compared With Ustekinumab in the Treatment of Moderate-To-Severe Plaque Psoriasis in Canada
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pss31 - Cost Per Responder of Secukinumab Compared to Other Biologics in Moderate-To-Severe Plaque Psoriasis From the Private Payer Perspective in Brazil
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Spotlight on Ixekizumab for the Treatment of Moderate-To-Severe Plaque Psoriasis: Design, Development, and Use in Therapy
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
Psy103 - Modelling Average Cost and Cost-Per-Responder for Biological Treatments for Moderate-To-Severe Plaque Psoriasis With Dose Escalation and Real-World Drug Survival
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
PSS14 Cost-Effectiveness of Biologic Therapies for the Treatment of Moderate to Severe Psoriasis in Germany
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pss32 - Cost-Effectiveness of Brodalumab for the Treatment of Moderate to Severe Plaque Psoriasis in Greece
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
540 Rapid Response in PASI, sPGA, and BSA Measures for Patients With Moderate-To-Severe Plaque Psoriasis With Ixekizumab
Journal of Investigative Dermatology
Biochemistry
Dermatology
Cell Biology
Molecular Biology
